Molecular Tumor Board
The Molecular Tumor Board consists of physician-scientists, clinicians and researchers in the field of tumor genetics.
Created in 2017, the board recommends advanced molecular testing for patients who meet certain criteria to help diagnose and manage central nervous system tumors. Various tests are performed to detect novel mutations and pathways involved in tumor growth, including rapid whole genome sequencing.
Robert Wechsler Reya, Ph.D., Director, Joseph Clayes III Research Center for Neuro-Oncology and Genomic Medicine; Director, Tumor Initiation and Maintenance Program Sanford Burnham Prebys (SBP) Medical Discovery Institute
John Crawford, M.D., M.S., Director, Neuro-Oncology Program
Jennifer Elster, M.D., Medical Director, Pediatric Proton Therapy Program
Michael Levy, M.D., Ph.D., Chief, Division of Neurosurgery
Denise Malicki M.D., Ph.D., Neuropathologist, Division of Pathology
David Dimmock, M.D., senior medical director of Rady Children’s Institute for Genomic Medicine
Jill Mesirov, Ph.D., UC San Diego School of Medicine
Hannah Carter Ph.D., UC San Diego School of Medicine
Pablo Tamayo Ph.D., UC San Diego School of Medicine
Lukas Chavez Ph.D., UC San Diego School of Medicine